Worsening Heart Failure Following Admission for Acute Heart Failure
A Pooled Analysis of the PROTECT and RELAX-AHF Studies
Beth A. Davison, Marco Metra, Gad Cotter, Barry M. Massie, John G.F. Cleland, Howard C. Dittrich, Christopher Edwards, Gerasimos Filippatos, Michael M. Givertz, Barry Greenberg, Piotr Ponikowski, Adriaan A. Voors, Christopher M. O’Connor, John R. Teerlink and on behalf of the PROTECT and RELAX-AHF Executive Committees
Association of WHF Through Day 5 With Other Clinical Outcomes
Mean differences or hazard ratios (HRs) with 95% confidence intervals (CIs) comparing patients with and without worsening heart failure (WHF) with respect to (A) length of initial hospital stay, (B) cardiovascular death or HF/renal failure rehospitalization through day 60, and (C) all-cause mortality through day 180. Pre-RELAX-AHF = Relaxin for the Treatment of Patients With Acute Heart Failure; PROTECT = Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function; RELAX-AHF = Relaxin in Acute Heart Failure.